Cardiotoxicity induced by multiple myeloma therapies: mechanistic convergence across proteasome inhibitors, CAR-T, and bispecific antibodies
{{output}}
Cardiovascular toxicity has emerged as an important obstacle to realizing the complete clinical potential of contemporary therapies for multiple myeloma (MM), including proteasome inhibitors (PIs), chimeric antigen receptor T-cell (CAR-T) therapies, and CD3-en... ...
